Jaimy Lee's profile photo

Jaimy Lee

New York

Deputy Editor, Newsletters at Endpoints News

Deputy editor @endpts. Alum: @MarketWatch, @LinkedIn

Featured in: Favicon endpts.com Favicon linkedin.com Favicon msn.com Favicon wsj.com Favicon yahoo.com (+1) Favicon marketwatch.com Favicon barrons.com Favicon morningstar.com Favicon campaignlive.co.uk Favicon prweek.com

Articles

  • Vera redraws the terms of up to $500M credit facility; Trevi aims to raise $100M

    5 days ago | endpoints.news | Jaimy Lee

    Plus, news about Kamari Pharma, Leyden Labs, Kiora, Senju, Alto Neuroscience, Chase Therapeutics, Nxera Pharma, Neurocrine Biosciences, Aytu BioPharma and Fabre-Kramer: On heels of pivotal … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

  • Gilead reveals plans to put another $11B into US manufacturing

    1 month ago | endpts.com | Jaimy Lee

    Gilead is the latest pharma company to announce that it’s pouring billions of dollars into its manufacturing and R&D operations in the US. Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

  • Bristol Myers Squibb to lay off over 500 workers in New Jersey

    1 month ago | endpts.com | Jaimy Lee

    Bristol Myers Squibb is letting go of 516 workers in New Jersey as part of a wide-reaching cost-cutting plan aimed at making the drugmaker more …Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

  • MoonLake discloses up to $500M in financing; OSR’s deal with innovation fund

    2 months ago | endpts.com | Jaimy Lee

    MoonLake Immunotherapeutics gets financing worth up to $500M: The company will get $75 million upfront from Hercules Capital. MoonLake, which went …Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

  • Acelyrin, Pliant turn to ‘poison pill’ as Kevin Tang’s Concentra pursues both companies

    2 months ago | endpts.com | Jaimy Lee

    Acelyrin and Pliant Therapeutics, both of which are viewed as takeover targets for Kevin Tang’s Concentra Biosciences, each adopted a “poison pill” on Thursday morning …Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →

X (formerly Twitter)

Followers
4K
Tweets
2K
DMs Open
No
Jaimy Lee
Jaimy Lee @jaimy_lee
8 Jan 25

So excited that @alexis_s_kramer has joined @endpts to steer our pharma coverage! She has a decade of experience covering law at Bloomberg Law, including working on stories about how various Trump drug pricing regulations were challenged in court. https://t.co/YBgTVl6h8v

Jaimy Lee
Jaimy Lee @jaimy_lee
19 Jul 24

RT @stefaniei: This is a travesty. #IStandWithEvan #JournalismIsNotACrime https://t.co/jSysZrWZEw via @WSJ

Jaimy Lee
Jaimy Lee @jaimy_lee
17 Apr 24

As ivermectin moves back into the news cycle, my story tracing the faulty science that led to the idea the drug successfully treats Covid: https://t.co/4n0AWZYROP